Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)

- First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2- Dosing of first

Related Keywords

China ,Australia ,Taiwan ,Nanjing ,Jiangsu ,Thailand ,Hughm Davis ,Wayne Saville ,Heidi Wang ,Biosion Syntracer ,Adagloxad Simolenin ,Biosion Inc ,Pharma Inc ,Business Development ,Biosion United States Inc ,Drug Administration ,High Throughput Endocytosis Platform ,Chief Business ,Development Officer ,Biosion United States ,Chief Medical Officer ,Chief Executive Officer ,Thailand Business ,